PRRT for grade 1–2, SSTR-positive metastatic gut NET needing surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1 trial tests PRRT, a targeted radiation treatment using somatostatin receptors, in people with metastatic gastrointestinal/pancreatic NETs who are also planning cytoreductive surgery. It aims to help shrink or control tumors by treating the cancer cells that take up the PRRT radiation signal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic gastroenteropancreatic NET (the cancer has spread to lymph nodes or liver)
- Your tumor is WHO grade 1 or 2, and your Ki-67 is 20% or less (a lab test)
- Your doctors think you’re a good candidate for surgery to remove as much tumor as possible (an R1-type goal)
- Your scans show measurable tumors and that all target spots have somatostatin receptors on a DOTA TATE PET scan
- You’re age 18 or older, able to do daily activities fairly well (ECOG 0–1), and your blood/organ tests are adequate
- You’ve been on octreotide long-acting injections (20 mg or 30 mg every 3–4 weeks) for at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Hear when a new Gastroenteropancreatic Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.